Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Open-label Study of SGN-35 in Japanese Patients with Relapsed/Refractory CD30-positive Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
jRCT2080221610Phase 2
- Sponsor
- Takeda
- Start
- Oct 2011
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), sponsored by Takeda.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on jRCT2080221610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221610.